Literature DB >> 21612409

Cytotoxic T-lymphocyte antigen-4 polymorphisms and susceptibility to osteosarcoma.

Yang Liu1, Zhimin He, Dapeng Feng, Guodong Shi, Rui Gao, Xiaodong Wu, Weiguo Song, Wen Yuan.   

Abstract

Despite the knowledge of many genetic alterations present in osteosarcoma, the complexity of this disease precludes placing its biology into a simple conceptual framework. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) plays important roles in downregulating T-cell activation, thereby attenuating anti-tumor responses and increasing cancer susceptibility. Polymorphisms in the CTLA-4 gene are associated with different autoimmune diseases and cancers. The current study evaluated the association of four CTLA-4 gene mutations, -1661A/G (rs4553808), -318C/T (rs5742909), +49G/A (rs231775), and CT60A/G (rs3087243), with osteosarcoma in the Chinese population. CTLA-4 polymorphisms were detected by polymerase chain reaction-restriction fragment length polymorphism in 267 osteosarcoma patients and 282 age-matched healthy controls. Results showed that the CTLA-4 gene +49 AA genotype, +49 A allele, and GTAG haplotype were significantly more frequent in osteosarcoma patients than in controls (odds ratio [OR] 2.20, 95% confidence interval [CI] 1.23-2.95, p = 0.007; OR 1.32, 95% CI 1.03-1.69, p = 0.029, and OR = 1.47, 95% CI 1.03-2.09, p = 0.033, respectively). The CTLA-4 +49G/A polymorphism and GTAG haplotype are associated with increased risk of osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21612409     DOI: 10.1089/dna.2011.1269

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  29 in total

1.  Fibroblast growth factor receptor 4 polymorphisms and susceptibility to coronary artery disease.

Authors:  Lan Ma; Haifeng Zhang; Carrie Han; Danian Tong; Meiyan Zhang; Yi'an Yao; Yu Luo; Xuebo Liu
Journal:  DNA Cell Biol       Date:  2012-02-07       Impact factor: 3.311

2.  Lysyl oxidase polymorphisms and ischemic stroke--a case control study.

Authors:  Hai-Feng Zhang; Kai-Jun Zhao; Yi Xu; Bo Hong; Wen-Yuan Zhao; Jian-Min Liu; Qing-Hai Huang
Journal:  Mol Biol Rep       Date:  2012-06-22       Impact factor: 2.316

3.  Interleukin 2 gene polymorphisms are associated with non-Hodgkin lymphoma.

Authors:  Haihan Song; Lei Chen; Zhanshan Cha; Jianwen Bai
Journal:  DNA Cell Biol       Date:  2012-04-03       Impact factor: 3.311

Review 4.  Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy.

Authors:  D Matthew Gianferante; Lisa Mirabello; Sharon A Savage
Journal:  Nat Rev Endocrinol       Date:  2017-03-24       Impact factor: 43.330

5.  Fibroblast growth factor receptor 4 polymorphisms and the prognosis of non-Hodgkin lymphoma.

Authors:  Zhanshan Cha; Yan Zang; Huijun Guo; Haihui Gu; Xiaohua Tu; Haihan Song; Baohua Qian
Journal:  Mol Biol Rep       Date:  2014-01-01       Impact factor: 2.316

6.  Effect of cytotoxic T-lymphocyte antigen-4, TNF-alpha polymorphisms on osteosarcoma: evidences from a meta-analysis.

Authors:  Jianwei Liu; Junli Wang; Weiping Jiang; Yujin Tang
Journal:  Chin J Cancer Res       Date:  2013-12       Impact factor: 5.087

7.  Programmed cell death 1 correlates with the occurrence and development of MG63 osteosarcoma.

Authors:  Fuyou Zhao; Qiong Wu; Xiusong Dai; Yumei Li; Huaiyong Gan; Ri Wang; Jie Lv; Yuqing Chen
Journal:  Oncol Lett       Date:  2016-10-24       Impact factor: 2.967

8.  Association of RECQL5 gene polymorphisms and osteosarcoma in a Chinese Han population.

Authors:  Li-Qiang Zhi; Wei Ma; Hong Zhang; Si-Xiang Zeng; Bo Chen
Journal:  Tumour Biol       Date:  2013-11-28

Review 9.  Translational biology of osteosarcoma.

Authors:  Maya Kansara; Michele W Teng; Mark J Smyth; David M Thomas
Journal:  Nat Rev Cancer       Date:  2014-10-16       Impact factor: 60.716

10.  Association between the cytotoxic T-lymphocyte antigen 4-318C/T polymorphism and malignant tumor risk.

Authors:  Taiming Li; Chengdi Wang; Zhenju Ren; Y I Ji; Chang Xu; Bing Xiao; Min Liu
Journal:  Biomed Rep       Date:  2016-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.